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Background: The risk of cardiovascular diseases (CVD) is increased tremendously among menopausal women, and
there is an increasing demand for alternative therapies for managing factors like dyslipidemia that contribute to
CVD development.
Methods: In this study, Nigella sativa was evaluated for its hypolipidemic effects among menopausal women. In a
randomised trial, hyperlipidemic menopausal women were assigned to treatment (n = 19) or placebo groups
(n = 18), and given N. sativa or placebo for two months after their informed consents were sought. At baseline,
blood samples were taken and at one month intervals thereafter until one month after the end of the study.
Results: The results showed that N. sativa significantly improved lipid profiles of menopausal women (decreased
total cholesterol, low density lipoprotein cholesterol and triglyceride, and increased high density lipoprotein
cholesterol) more than the placebo treatment over 2 months of intervention. One month after cessation of
treatment, the lipid profiles in the N. sativa-treated group tended to change towards the pretreatment levels.
Conclusions: N. sativa is thought to have multiple mechanisms of action and is cost-effective. Therefore, it could
be used by menopausal women to remedy hypercholesterolemia, with likely more benefits than with single
pharmacological agents that may cause side effects. The use of N. sativa as an alternative therapy for
hypercholesterolemia could have profound impact on the management of CVD among menopausal women
especially in countries where it is readily available.
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The incidence of cardiovascular diseases (CVD) rises sig-
nificantly in women when they attain menopause. Also,
CVD continues to cause significant morbidity and mor-
tality in those women [1,2]. In fact, the incidence of
CVD is higher in menopausal women compared to
women of other age groups and men of similar ages [3].
CVD is projected to remain the single leading cause of
death globally and by 2020 almost 23.6 million people* Correspondence: myhome.e@gmail.com
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unless otherwise stated.are projected to die from CVD particularly heart disease
and stroke (WHO Death Estimated Report, 2011) [4]
with significant impacts on the lives of women. The in-
crease in CVD risk among menopausal women is mostly
due to estrogen deprivation, which directly affects CVD
risk factors such as dyslipidemia, diabetes mellitus, over-
weight, or hypertension at the time of menopause [5].
Dyslipidemia arises as a result of abnormal blood lipid
profiles including especially those of high density lipo-
protein (HDL), low density lipoprotein (LDL), and tri-
glycerides (TG) [6,7], and remains one of the most
important factors responsible for increased CVD risk
among menopausal women. In Malaysia, CVD was re-
ported to account for 25% of all deaths in 2008 (NCVD
ACS Registry 4th Annual Report, 2011) and dyslipidemial Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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betes were reported to be the main factors responsible
[8]. Particularly, it is reported that an increasing number
of Malaysian women are suffering from CVD, likely due
to rising standards of living, increasing longevity and
better health care, which ensures detection of more
cases [9]. The use of pharmacological agents remains the
standard treatment option for dyslipidemia, however,
problems of side effects have necessitated the search for
better options [10].
Although it is a physiological transition in a woman’s
life, menopause is accompanied by problems, and hence
women at this age must be managed appropriately for
any health risks or problems, to ensure a fulfilling life.
Nowadays, there is an increasing demand for plant bior-
esources in the management of chronic diseases like
CVD, instead of synthetic drugs, to avoid side effects
[11]. Moreover, traditional medicinal plants are often
cheaper, locally available, and easily consumable (raw or
as simple medicinal preparations). In line with this, Ni-
gella sativa commonly known as black seed has been
widely used in many Asian, Middle Eastern and Far
Eastern countries as a spice and food preservative as
well as a health remedy in traditional medicine for the
treatment of numerous disorders. This plant has been a
great focus of research and has several traditional uses
and consequently has been studied extensively for its
therapeutic properties [12]. Its medicinal benefits result
from its rich and diverse chemical composition includ-
ing amino acids, proteins, carbohydrates, and crude
fiber, oils (fixed oil with 36-38% composed of unsatur-
ated fatty acids), minerals, alkaloids, saponin and others
[13]. Furthermore, many studies have shown good po-
tential of hypoglycaemia, hypocholesterolemia and anti-
oxidant effects of N. Sativa, which contribute to its
cardioprotective effects [14-16]. However, little informa-
tion exists concerning the effects of N. sativa on lipid
parameters of menopausal women. Thus, we studied the
effects of N. sativa seed powder on serum cholesterol,
HDL-and LDL-cholesterol and TG in menopausal
women for possible hypolipidemic activity.
Materials and method
Formulation of N. sativa and placebo capsules
Seeds of N. sativa were imported from Iran through a
local company named Sari Tani Desa SDN BHD located
in Shah Alam, Malaysia. Voucher specimens of seeds
were kept at the Laboratory of Molecular Biomedicine,
Institute of Bioscience, Universiti Putra Malaysia and the
seed was identified and authenticated by Professor Dr.
Maznah Ismail, Head of the Laboratory of Molecular
Biomedicine, Institute of Bioscience, Universiti Putra
Malaysia, Malaysia. Further, N. sativa seeds were proc-
essed into pharmaceutical grade capsules containingN. sativa powder and bottled according to Good Manu-
facturing Practices (GMP No.: MALLP20121468). Each
capsule was prepared containing 500 mg powder of N.
Sativa, and each bottle contained 60 capsules, stock for
a month period to help with compliance of the respon-
dents. While for the placebo, we used wheat germ which
was bought from the same company, Sari Tani Desa
Sdn. Bhd. and the entire process of wheat germ capsula-
tion was same as N. sativa seeds, however with lesser
dose of 100 mg per capsule.
Chemicals
All chemicals used in this study were of analytical grade,
and procured from Fisher Scientific (Loughborough,
UK) and Merck (Darmstadt, Germany). Reagents and
diagnostics kits used for TC, LDL, HDL and TG were
supplied by Randox Laboratories Limited (Crumlin,
County Antrim, UK).
Study subjects and protocol
This clinical trial was conducted at Pusat Kesihatan Universiti
(PKU), Universiti Putra Malaysia (UPM). Ethical clear-
ance was obtained from the Faculty of Medicine and
Health Sciences Medical Research Ethics Committee to
conduct this study (approval number: JKEUPM/LEC-
T_AUG [08]04), which aimed to evaluate the hypolipid-
emic effects of N. sativa in menopausal women. Thirty
seven women (n = 37), who were menopausal for at
least ≥ 12 months, within the age range of 45–60 years
and who presented with moderate risk of hyperlipid-
emia were chosen as respondents in this study. Respon-
dents were non-smokers, did not consume alcohol and
did not have a history of any other chronic disease or
drug/herb ingestion. Those with any of the features
above were excluded from the study. These subjects
were recruited among the university’s staff or ex-staff
based on a health screening. Each qualified subject was
informed about the study verbally and in writing ac-
cording to Good Clinical Practice. These selected sub-
jects were randomized into 2 groups (treatment and
placebo) as follows: treatment group received capsu-
lated N. sativa powder (n = 19), while the placebo group
(n = 18) received the placebo capsules. The physical and
pathological histories of these subjects were recorded,
and their baseline anthropometric parameters measured
(Table 1). All subjects were requested to maintain their
regular lifestyles including their dietary intake and phys-
ical activity. Capsules of N. sativa powder were orally
administered at a dose of 1 g after breakfast every day
for a period of two months. A follow- up assessment
was done after the subjects completed two months
treatment. Fasting venous blood (5 ml) was drawn from
the subjects at baseline and at intervals during (1 month
of treatment) and after the treatment period (at the end






Age (mean years) 53.22 ± 2.16 53.71 ± 3.57
Body weight (kg) 63.07 ± 8.73 64.85 ± 10.69
BMI (kg/m2) 27.18 ± 4.34 27.75 ± 4.38
Fat percentage (%) 37.39 ± 8.86 39.48 ± 8.00
Duration of menopause (%)
1-5 years 89.48 94.44
















Data presented as mean ± SD for age, body weight, BMI and fat percentage,
BMI: body mass index.
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of study) for further analyses. Furthermore, at each fol-
low up interval, blood pressure measurements were
taken (Table 2).
Biochemical analysis
Whole blood was collected in plain tubes and further
centrifuged at 2500 rpm for 15 min under 25°C. Serum
was collected for the analyses of TC, TG, HDL and LDL
levels using commercial diagnostic kits (Randox Labora-
tories Limited, Crumlin, County Antrim, UK) on Selec-
tra XL chemical analyzer (Vita Scientific, Dieren, theTable 2 Treatment effects of Nigella sativa and placebo on fa
Parameters Baseline 1st month
N. sativa Placebo N. sativa Placeb
FBG (mmol/L) 6.37 ± 0.61* 5.94 ± 0.44 5.69 ± 0.43* 5.81 ± 0
SBP (mmHg) 129.33 ± 15.44 138.40 ± 18.90 121.80 ± 17.40 131.27 ±
DBP (mmHg) 77.13 ± 9.16 83.93 ± 15.73 76.00 ± 12.90 79.53 ± 1
Values are mean ± SD. There was a downward trend in the means of the groups for
differences were observed.
*Significant between N. S vs. placebo group at p < 0.05. SBP: systolic blood pressureNetherlands). Fasting blood glucose was determined
using a glucometer (Roche Diagnostics, Indianapolis, IN,
USA).
Statistical analysis
All experimental values are presented as means ± stand-
ard deviation (SD). Statistical analysis was performed
using SPSS windows program version 19 (SPSS Institute,
Inc., Chicago, IL, USA). The One-way Analysis of Vari-
ance (ANOVA) with Bonferroni correction was used for
analysis of data. Difference was considered to be signifi-
cant if p < 0.05.
Results
This study was an attempt at determining the effects of
N. sativa seeds powder on lipid profiles in humans espe-
cially among those with an increased risk of dyslipidemia
(menopausal women). The baseline characteristic of the
respondents in both treatment and placebo groups are
presented in Table 1. Mean age of respondents in treat-
ment and placebo groups participated in this study were
53.22 ± 2.16 and 53.71 ± 3.57, respectively. The changes
in serum TC, TG, LDL and HDL are summarized in
Figures 1, 2, 3, 4 for both treatment and placebo groups.
Mean TC of the N. sativa and placebo groups at base-
line, 1st and 2nd months of treatment and one month
after treatment ended (follow-up) were 6.09 ± 1.04,
5.69 ± 0.99, 5.11 ± 0.91, and 5.61 ± 0.79; placebo was
6.06 ± 1.02, 5.88 ± 0.77, 5.79 ± 0.68 and 5.84 ± 0.49 mmol/
L, respectively. Mean TC of the respondents in the N.
sativa group improved significantly, p < 0.05, by 16.09% at
two months of treatment compared to baseline and sig-
nificantly greater, p < 0.05, than that in placebo group.
Mean TG values of the N. sativa and placebo groups at
baseline, 1st and 2nd months of treatment and follow-up
were 1.76 ± 0.35, 1.54 ± 0.31, 1.37 ± 0.24, and 1.29 ± 0.35;
1.72 ± 0.53, 1.68 ± 0.46, 1.56 ± 0.24 and 1.47 ± 0.51 mmol/
L, respectively. Similar trend of reduction in TG levels
(22.16%) as TC levels was observed with two months
treatment with N. sativa seeds powder which was signifi-
cantly greater, p < 0.05, than the placebo group.
While, mean changes of LDL-C in the treatment
groups at baseline, 1st and 2nd months of treatment and
follow-up were 4.65 ± 0.89, 3.89 ± 0.83, 3.41 ± 0.76 andsting blood glucose (FBG) and blood pressure levels
2nd month Follow up
o N. sativa Placebo N. sativa Placebo
.31 5.03 ± 0.51* 5.73 ± 0.75 5.48 ± 0.42* 5.70 ± 0.66
19.22 124.53 ± 13.31 140.71 ± 11.85 125.84 ± 15.48 144.71 ± 19.84
3.83 75.53 ± 9.56 89.00 ± 12.53 75.98 ± 10.64 93.00 ± 15.16
both N. sativa and placebo over 2 months of intervention but no significant
; DBP: diastolic blood pressure.
Figure 1 Changes in serum total cholesterol (TC); menopausal
women randomly assigned to Nigella sativa (N.S) or placebo
groups were treated for 2 months and blood samples taken at
baseline, and 1 and 2 months after the start of the
intervention, and one month after cessation of intervention
(FL), and used to evaluate serum TC. Results are expressed as
mean ± SD. *significant between N. S vs. placebo group at p < 0.05.
Different letters on bars representing different intervals for the same
group indicate significant difference between the intervals for the
same treatment (p < 0.05).
Figure 3 Changes in serum low density lipoprotein (LDL);
menopausal women randomly assigned to Nigella sativa (N.S)
or placebo groups were treated for 2 months and blood
samples taken at baseline, and 1 and 2 months after the start
of the intervention, and one month after cessation of
intervention (FL), and used to evaluate serum LDL. Results are
expressed as mean ± SD. *significant between N. S vs. placebo group
at p < 0.05. Different letters on bars representing different intervals
for the same group indicate significant difference between the
intervals for the same treatment (p < 0.05).
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4.39 ± 0.28 mmol/L, respectively. Reduction of LDL-C
was 26.67% with significant changes, p < 0.05 with two
months of treatment of N. sativa seeds powder in com-
parison to baseline. Again, the improvements in LDL-C
throughout the treatment period were significantly
greater, p < 0.05 in the N. sativa group compared to the
placebo group.Figure 2 Changes in serum triglyceride (TG); menopausal
women randomly assigned to Nigella sativa (N.S) or placebo
groups were treated for 2 months and blood samples taken at
baseline, and 1 and 2 months after the start of the
intervention, and one month after cessation of intervention
(FL), and used to evaluate serum TG. Results are expressed as
mean ± SD. *significant between N. S vs. placebo group at p < 0.05.
Different letters on bars representing different intervals for the same
group indicate significant difference between the intervals for the
same treatment (p < 0.05).Finally, HDL-C levels in both respective treatments at
baseline, 1st and 2nd months of treatment and follow-up
were 1.31 ± 0.22, 1.33 ± 0.30, 1.41 ± 0.25 and 1.47 ± 0.26;
1.32 ± 0.25, 1.34 ± 0.19, 1.35 ± 0.25 and 1.38 ± 0.27 mmol/
L, respectively. HDL-C was found to have improved
slightly in both groups, but no significant changes (p >
0.05) were observed between the two groups. Overall,
improvements of lipid profile (TC, TG and LDL-C)Figure 4 Changes in serum high density lipoprotein (HDL);
menopausal women randomly assigned to Nigella sativa (N.S)
or placebo groups were treated for 2 months and blood
samples taken at baseline, and 1 and 2 months after the start
of the intervention, and one month after cessation of
intervention (FL), and used to evaluate serum HDL. Results are
expressed as mean ± SD. *significant between N. S vs. placebo group
at p < 0.05. Different letters on bars representing different intervals
for the same group indicate significant difference between the
intervals for the same treatment (p < 0.05).
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p < 0.05 in the N. sativa group compared to the placebo
group except for HDL-C levels, which was similar to that
produced by placebo.
Although the differences in blood pressures (Table 2)
were not significant between the N. sativa-treated group
and the control over the period of intervention, N. sativa
produced better results and significant changes were ob-
served in fasting blood glucose. The changes in these pa-
rameters also showed similar patterns to those of lipid
profile; over the 2 months of intervention, the changes
showed a downward trend but increased 1 month after
cessation of intervention.
Discussion
Menopause begins 12 months after a woman's final
menstrual period and is associated with a dramatic drop
in estrogen levels. This change in hormone levels often
contributes to adverse metabolic changes that occur dur-
ing the transitional pre- and post-menopausal periods,
which make women prone to diseases. It has been pro-
posed that estrogen hormone may be responsible for the
protective effects seen amongst pre-menopausal women
[17]. Estrogen exerts cardio-protective action by main-
taining high levels of HDL and lower levels of LDL and
TG. As can be recalled, loss of this protection after
menopause may therefore be responsible for increased
risk of developing CVD in menopausal women [18].
Moreover, cross-sectional studies have shown high TC,
and LDL and TG levels are associated with menopausal
status [19,20]. Longitudinal studies also showed in-
creased TC, LDL, or TG levels were common at the
time of menopause [21,22].
In this study, we determined the hypolipidemic effects
of N. sativa in menopausal women as part of the increas-
ing drive to provide better insights into the effects of plant
bioresources on health, and their potential use for therapy
of chronic diseases. Also, increasing numbers of women
are thought to use complementary medicines for disorders
associated with their menopause, and studies like these
could provide evidence-based rationale for their choice of
plant bioresources. Specifically, about 75% of women were
reported to be using herbal and complementary medicines
in their menopausal period in place of hormone replace-
ment therapy (HRT) due to considerations on its side
effects [23]. Furthermore, the baseline data from partici-
pants in the Study of Women’s Health Across the Nation
(SWAN) indicated that 48.5% had used at least one com-
plementary or alternative therapy during their menopausal
years [24]. Moreover, N. sativa proved to have many bene-
ficial health effects, particularly as hypolipidemic agent in
various clinical trials [25,26]. To our knowledge, no clin-
ical studies have examined the effect of N. sativa seed
powder on hyperlipidemic menopausal women, while onlya few have assessed the effect of N. sativa in overriecto-
mized rats [27]. With the apparent lack of data on the ef-
fect of N. sativa in menopausal women, this study was
necessitated to determine the protective effects of N.
sativa on hyperlipidemic menopause women. The import-
ance of this study is underlined by the fact that the overall
cause of hyperlipidemia and the mechanisms leading up
to its development in menopausal women differ consider-
able from in premenopausal women or men in general.
The results of the present study showed significant de-
crease in hyperlipidemia among menopausal women fol-
lowing treatment with N. Sativa, compared to the
placebo group. The results also indicated a tendency for
N. sativa to improve glycemia and blood pressure better
than the placebo. Our results are in keeping with those
of Inayat et al. (2009), who reported that oral treatment
with N. sativa powder in hypercholesterolemic patients
at the dose of 1 g daily for two months was found to re-
duce TC, LDL and TG, and increase HDL to highly sig-
nificant extents [28]. Furthermore, TC, LDL and TG
were reduced significantly after 6 months of treatment
with N. sativa powder (500 mg) and statin in cardiac pa-
tients visiting Ch. Pervaiz Elahi Institute of Cardiology,
Multan, Pakistan compared to placebo group receiving
statin only [29]. In another study of 8 weeks at the
Chamran Hospital (Isfahan, Iran), it was suggested that
treatment with an oral N. sativa seed extract in male pa-
tients with mild hyperlipidemia and hypertension caused
a significant dose-dependent decline in the levels of TC,
TG and LDL relative to baseline data [30].
The hypolipidemic effects of N. sativa seeds powder
does not seem to be due only to one component, but ra-
ther likely due to synergistic action of its different con-
stituents including thymoquinone (TQ), migellamine,
soluble fiber (mucilage), sterols, flavanoids and high con-
tent of polyunsaturated fatty acids (PUFAs) [31]. Add-
itionally, in a previous study, we demonstrated that TQ
in combination with other bioactive compounds in a
formulation called TQ-rich fraction produced better
regulation of cholesterol synthesis [32-34]. Multiple
mechanisms of action may in fact contribute to the
lipid-lowering effects of N. sativa. Earlier, we demon-
strated that N. sativa was able to regulate cholesterol
synthesis through regulation of HMG-CoA reductase,
Apo-A1, Apo-B100 and LDL-receptor genes, an effect
mediated by TQ and other N. sativa constituents
[32-34]. In fact, our study had demonstrated that TQ in
combination with other bioactive compounds weas bet-
ter at regulation of cholesterol synthesis than TQ alone,
suggesting that synergy of the compounds enhances the
cholesterol-lowering effects of N. sativa [33,34]. In
addition to the control of cholesterol synthesis we have
demonstrated, other mechanisms of hypolipidemic ac-
tion of TQ, the active components of N. sativa, have
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lipid peroxidation in liposome and works as a scavenger
of various reactive oxygen species including superoxide
anion and hydroxyl radicals [32]. Antioxidants may also
partly contribute to the overall functional effects of N.
Sativa. Particularly, antioxidants (flavonoids) have been
proposed to decrease cholesterol synthesis and suppress
reactive oxygen species, nitrogen species formation and
protect the antioxidant defence system [35]. Flavanoids
are also thought to enhance the efficiency of liver cells
to remove LDL from the blood circulation by increasing
LDL receptor densities in the liver and binding to apoli-
poprotein B [36]. Lipid lowering effects of dietary sol-
uble fibers [37] and sterols [38] in N. sativa could also
contribute to decreased dietary cholesterol absorption,
increased primary bile synthesis and its fecal losses. Be-
sides, high content of PUFAs in N. sativa may also re-
sult in decreased serum TC [39,40].
Conclusions
The present study showed that N. sativa caused signifi-
cant decrease in TC, LDL and TG, and slight increase in
HDL among menopausal women receiving N. sativa
powder at a dose of 1 g daily for two months compared
to placebo group. The study also demonstrated that N.
sativa may improve other biochemical indices like gly-
cemia and blood pressure in menopausal women. With
an increasing demand for more alternative therapies for
menopausal women due to concerns of side effects with
pharmacological therapies, and considering that multiple
factors play a role in the development and complication
of hyperlipidemia among menopausal women, N. sativa
may be used by hyperlipidemic menopausal women as a
good complementary therapy. N. sativa is an easily avail-
able and cost-effective remedy to treat dyslipidemia, and
its proposed multiple mechanisms of action may pro-
duce better hypolipidemic effects compared to standard
pharmacological agents or other medicinal plants with a
single mechanism of action. Studies like these contribute
to better understanding of N. sativa effectiveness as a
therapeutic agent, and could lead to its widespread use
all over the world.
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